Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335358 | 0.89 | EPHX2 (0.53) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL334723 | 0.88 | EPHX2 (0.52) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL335475 | 0.85 | EPHX2 (0.59) | EPHX2PPARGLMNASMN1; SMN2POLB | |
| SCHEMBL12333260 | 0.85 | SMN1; SMN2 (0.60) | EPHX2PPARGNPC1SMN1; SMN2PPARA | |
| SCHEMBL3743612 | 0.84 | EPHX2 (0.49) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL334806 | 0.84 | LMNA (0.51) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL6127325 | 0.84 | LMNA (0.54) | EPHX2PPARGLMNANPC1L3MBTL1 | |
| SCHEMBL335020 | 0.82 | LMNA (0.49) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL334591 | 0.81 | LMNA (0.47) | EPHX2PPARGLMNANPC1SMN1; SMN2 | |
| SCHEMBL15933205 | 0.80 | EPHX2 (0.73) | EPHX2PPARGLMNAPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | EPHX2 1754/4885PPARG 265/4885LMNA 4759/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | EPHX2 1124/4885PPARG 1586/4885LMNA 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.